| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5767251 | ORGANON USA INC | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
Jun, 2015
(8 years ago) | |
| US5929028 | ORGANON USA INC | Liquid gonadotropin containing formulations |
Jan, 2018
(6 years ago) | |
| US7563763 | ORGANON USA INC | FSH and FSH variant formulations, products and methods |
Aug, 2019
(4 years ago) | |
| US7446090 | ORGANON USA INC | FSH formulation |
Aug, 2019
(4 years ago) | |
Follistim Aq is owned by Organon Usa Inc.
Follistim Aq contains Follitropin Alfa/Beta.
Follistim Aq has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Follistim Aq are:
- US5767251
- US5929028
- US7563763
- US7446090
Follistim Aq was authorised for market use on 26 August, 2005.
Follistim Aq is available in injectable;subcutaneous dosage forms.
Follistim Aq can be used as treatment of infertility through induction of ovulation and pregnancy to anovulatory infertile women, a method for administering follicle stimulating hormone (fsh) for ovarian follicle or testicular stimulation in the human.
The generics of Follistim Aq are possible to be released after 23 August, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-306) | Jun 28, 2013 |
Drugs and Companies using FOLLITROPIN ALFA/BETA ingredient
Market Authorisation Date: 26 August, 2005
Treatment: Treatment of infertility through induction of ovulation and pregnancy to anovulatory infertile women; A method for administering follicle stimulating hormone (fsh) for ovarian follicle or testicular s...
Dosage: INJECTABLE;SUBCUTANEOUS
FOLLISTIM AQ family patents
